BRAIN Biotech AG
XETRA:BNN
BRAIN Biotech AG
XETRA:BNN
Price:
2.82 EUR
0.71%
Updated:
May 3, 2024
BRAIN Biotech AG
Income from Continuing Operations
|
BRAIN Biotech AG
Income from Continuing Operations Peer Comparison
Comparables:
WCH
EVK
1COV
ACT
SY1
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
BRAIN Biotech AG
XETRA:BNN
|
Income from Continuing Operations
-€8.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Wacker Chemie AG
XETRA:WCH
|
Income from Continuing Operations
€327.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
5%
|
CAGR 10-Years
48%
|
|
|
Evonik Industries AG
XETRA:EVK
|
Income from Continuing Operations
-€452m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Covestro AG
XETRA:1COV
|
Income from Continuing Operations
-€202m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AlzChem Group AG
XETRA:ACT
|
Income from Continuing Operations
€34.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Symrise AG
XETRA:SY1
|
Income from Continuing Operations
€344.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
See Also
What is BRAIN Biotech AG's Income from Continuing Operations?
Income from Continuing Operations
-8.3m
EUR
-8.3m
EUR
Based on the financial report for Dec 31, 2023, BRAIN Biotech AG's Income from Continuing Operations amounts to -8.3m EUR.
What is BRAIN Biotech AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
2%
2%
Over the last year, the Income from Continuing Operations growth was -28%. The average annual Income from Continuing Operations growth rates for BRAIN Biotech AG have been 6% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
